News

This patent, with a priority date of 2008, covers screening mechanisms for identification of small molecules that can modulate the function of a nuclear receptor target that was

Data from 50 patients treated at 15 centers are being presented at the European Hematology Association (EHA) Annual Congress in Vienna. A copy of the poster, entitled "Updated

A total of 255 subjects have been enrolled, which exceeds the goal of 250 subjects that were planned for participation. The National Institute of Neurological Disorders and Stroke

After the respective agreement, both Proteus and Boston Children’s Hospital will remain as key members of the collaboration steering committee. The agreement includes about $85m in upfront and

SYN-004 is designed to degrade certain intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of

Resunab is a new synthetic oral drug that has the potential to treat chronic inflammation and fibrosis. Systemic sclerosis causes fibrosis of skin and internal organs, affecting predominately

Under the deal, OA Centers of America will include Gensco’s patented Transdermal products (SpeedGel Rx and LiDORx) as an option to show improved patient outcomes and economic value

The results showed patients with relapsed/refractory CLL taking venetoclax in combination with rituximab, had an overall response rate (ORR) of 84%. In addition, six patients stopped venetoclax after

Currently, the company is carrying out a multicenter, randomized, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SER-109 in prevention of recurrent CDI. The